Normal cerebrospinal fluid levels of insulin in patients with Parkinson's disease

Journal of Neural Transmission

Volumn 107, Issue 4, 2000, Pages 445-449

  Jimenez Jimenez F J ^a,c   Molina, J A ^b   Vargas, C ^b   Gomez P ^b   De Bustos, F ^b   Zurdo, M ^a   Gomez Escalonilla C ^b   Barcenilla, B ^a   Berbel, A ^b   Camacho, A ^b   Arenas, J ^b  

^a UNIVERSITY OF ALCALÁ   (Spain)

^b HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^c C/ Corregidor Jose de Pasamonte   (Spain)

Author keywords

Cerebrospinal fluid levels; Insulin; Parkinson's disease

Indexed keywords

ANTIPARKINSON AGENT; INSULIN;

ADULT; AGE; AGED; ARTICLE; CEREBROSPINAL FLUID LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE DURATION; DISEASE SEVERITY; FEMALE; HUMAN; MALE; ONSET AGE; PARKINSON DISEASE; PRIORITY JOURNAL; RADIOIMMUNOASSAY; RATING SCALE;

EID: 0034108740     PISSN: 03009564     EISSN: None     Source Type: Journal    
DOI: 10.1007/s007020070086     Document Type: Article

References (14)

1. Blum-Degen D, Frolich L, Hoyer S, Riederer P (1995) Altered regulation of brain glucose metabolism as a cause of neurodegenerative disorders? J Neural Transm 46 [Suppl]: 139-147
2. Boyd AE III, Lebovitz HE, Feldman JM (1971) Endocrine function and glucose metabolism in patients with Parkinson's disease and their alteration by L-Dopa. J Clin Endocrinol Metab 33: 829-837
3. Fahn S, Elton RL, and members of the UPDRS Development Committee (1987) Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD, Goldstein M, Calne DB (eds) Recent developments in Parkinson's disease, vol II. McMillan, Florham Park, pp 153-163
4. Hoehn MM, Yahr MD (1967) Parkinsonism: onset, progression and mortality. Neurology 17: 427-442
5. Hughes AJ, Ben-Shlomo SE, Daniel SE, Lees AJ (1992) What features improve the accuracy of clinical diagnosis in Parkinson's disease? A clinicopathological study. Neurology 42: 1142-1146
6. Kansal PC, Buse J, Talbert OR, Buse MG (1972) The effect of L-dopa on plasma growth hormone, insulin, and tyroxine. J Clin Endocrinol Metab 34: 99-105
7. Moreu E, Molinero IM, Fernández E (1990) R-Sigma: Base de datos bioes-tadística para un ordenador personal. Horus Hardware, Madrid
8. Moroo I, Yamada T, Makino H, Tooyama I, McGeer PL, McGeer EG, Hirayama K (1994) Loss of insulin receptor immunoreactivity from the substanda nigra pars compacta neurons in Parkinson's disease. Acta Neuropathol (Berl) 87: 343-348
9. Reiser M, Lenz E, Bernstein HG, Dorn A (1985) Insulin-like immunoreactivity in human cerebrospinal fluid is independent of insulin blood levels. Hum Neurobiol 4: 53-55
10. Rosati G, Maioli M, Aiello I, Farris A, Agnetti V (1976) Effects of long-term L-dopa therapy on carbohydrate metabolism in patients with Parkinson's disease. Eur Neurol 14: 229-239
11. Sandyk R (1993) The relationship between diabetes mellitus and Parkinson's disease. Int J Neurosci 69: 125-130
12. Sirtori CR, Bolme P, Azarnoff DL (1972) Metabolic response to acute and chronic L-dopa administration in patients with parkinsonism. N Engl J Med 287: 729-833
13. Takahashi M, Yamada T, Tooyama T, Moroo I, Kimura H, Yamamoto T, Okada H (1996) Insulin receptor mRNA in the substantia nigra in Parkinson's disease. Neurosci Lett 204: 201-204
14. Van Woert MV, Mueller PS (1971) Glucose, insulin, and free fatty acid metabolism in Parkinson's disease treated with levodopa. Clin Pharmacol Ther 12: 360-367